Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CBLB | Q13191 | 20/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27308772 | 0.93 | CBLB (0.54) | CBLB | |
| SCHEMBL30956954 | 0.93 | CBLB (0.54) | CBLB | |
| SCHEMBL27295793 | 0.92 | CBLB (0.54) | CBLB | |
| SCHEMBL27318557 | 0.92 | CBLB (0.52) | CBLB | |
| SCHEMBL27294116 | 0.91 | CBLB (0.51) | CBLB | |
| SCHEMBL29920028 | 0.91 | CBLB (0.57) | CBLB | |
| SCHEMBL29920421 | 0.91 | CBLB (0.57) | CBLB | |
| SCHEMBL29920256 | 0.89 | CBLB (0.56) | CBLB | |
| SCHEMBL29920362 | 0.89 | CBLB (0.62) | CBLB | |
| SCHEMBL27086276 | 0.89 | CBLB (0.62) | CBLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250263399-A1 | CBL-B MODULATORS AND USES THEREOF | SCHRÖDINGER, INC. | 2025-08-21 | — | — | US | disclosed |
| US-12325697-B2 | CBL-B modulators and uses thereof | NIMBUS CLIO, INC. (US) | 2025-06-10 | — | — | US | disclosed |
| CN-117858707-A | CBL-B modulators and uses thereof | 林伯士克莱奥公司 | 2024-04-09 | — | — | CN | disclosed |
| US-20230086064-A1 | CBL-B MODULATORS AND USES THEREOF | NIMBUS DISCOVERY, INC. | 2023-03-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230086064-A1 | CBL-B MODULATORS AND USES THEREOF | CBLB, CBL, CBLC | CBLB 1/4885 |
| US-20250263399-A1 | CBL-B MODULATORS AND USES THEREOF | CBLB, CBL, CBLC | CBLB 1/4885 |
| US-12325697-B2 | CBL-B modulators and uses thereof | CBLB, CBL, CBLC | CBLB 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.